Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Jul;37(1):17-40.
doi: 10.2165/00003088-199937010-00002.

Pharmacokinetics of Opioids in Liver Disease

Affiliations
Review

Pharmacokinetics of Opioids in Liver Disease

I Tegeder et al. Clin Pharmacokinet. .

Abstract

The liver is the major site of biotransformation for most opioids. Thus, the disposition of these drugs may be affected in patients with liver insufficiency. The major metabolic pathway for most opioids is oxidation. The exceptions are morphine and buprenorphine, which primarily undergo glucuronidation, and remifentanil, which is cleared by ester hydrolysis. Oxidation of opioids is reduced in patients with hepatic cirrhosis, resulting in decreased drug clearance [for pethidine (meperidine), dextropropoxyphene, pentazocine, tramadol and alfentanil] and/or increased oral bioavailability caused by a reduced first-pass metabolism (for pethidine, dextropropoxyphene, pentazocine and dihydrocodeine). Although glucuronidation is thought to be less affected in liver cirrhosis, and clearance of morphine was found to be decreased and oral bioavailability increased. The consequence of reduced drug metabolism is the risk of accumulation in the body, especially with repeated administration. Lower doses or longer administration intervals should be used to remedy this risk. Special risks are known for pethidine, with the potential for the accumulation of norpethidine, a metabolite that can cause seizures, and for dextropropoxyphene, for which several cases of hepatotoxicity have been reported. On the other hand, the analgesic activity of codeine and tilidine depends on transformation into the active metabolites, morphine and nortilidine, respectively. If metabolism is decreased in patients with chronic liver disease, the analgesic action of these drugs may be compromised. Finally, the disposition of a few opioids, such as fentanyl, sufentanil and remifentanil, appears to be unaffected in liver disease.

Similar articles

See all similar articles

Cited by 54 articles

See all "Cited by" articles

References

    1. Br J Anaesth. 1982 Aug;54(8):871-7 - PubMed
    1. Clin Pharmacol Ther. 1975 Mar;17(3):258-66 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jul;354(2):192-7 - PubMed
    1. Anesthesiology. 1996 Apr;84(4):812-20 - PubMed
    1. Br J Clin Pharmacol. 1989 Dec;28(6):629-37 - PubMed
Feedback